28 completed. 28 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 28 | Completed 28 |
Follow Charcoal: new trials by email Literature Review of Charcoal trials Research Report on Charcoal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension) budesonide, Activated Charcoal - Healthy | Phase 1 | Completed | Unither Pharmaceuticals, France | 24 | 2024-08-13 | 2024-11-08 |
| Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal) - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | AstraZeneca | 108 | 2022-07-29 | 2025-08-28 |
| A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants Mavacamten, Activated Charcoal with Sorbitol - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 45 | 2022-04-15 | 2022-11-08 |
| Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product Indacaterol/glycopyrronium - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 24 | 2022-02-28 | 2022-07-13 |
| Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics. Rivaroxaban, Activated charcoal - Healthy | Phase 1 | Completed | Centre Hospitalier Universitaire de Saint Etienne | 12 | 2022-01-03 | 2022-12-05 |
| Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler Indacaterol maleate and glycopyrronium bromide, Ultibro Breezhaler with oral charcoal - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 34 | 2021-05-07 | 2021-09-28 |
| Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler® Tiotropium Bromide Monohydrate, Tiotropium Easyhaler with oral activated charcoal - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 43 | 2021-04-26 | 2021-10-25 |
| To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men. Combined oral contraceptives (COC), Moxifloxacin 400mg, Cenerimod 0.5 mg - Healthy Subjects | Phase 1 | Completed | Viatris Innovation GmbH | 97 | 2020-01-31 | 2025-09-22 |
| Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects Sotagliflozin (SAR439954), 14C-microtracer, Charcoal - Type 2 Diabetes Mellitus, Healthy Subjects | Phase 1 | Completed | Sanofi | 6 | 2019-01-14 | 2022-04-25 |
| Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus Salmeterol/fluticasone Easyhaler, Salmeterol/fluticasone Easyhaler with charcoal, Seretide Diskus - Asthma | Phase 1 | Completed | Orion Corporation, Orion Pharma | 64 | 2016-07-01 | 2017-03-03 |
| Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects GSK2269557 ELLIPTA DPI, Placebo ELLIPTA DPI, Activated charcoal - Pulmonary Disease, Chronic Obstructive | Phase 1 | Completed | GlaxoSmithKline | 22 | 2016-03-14 | 2017-04-26 |
| Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects rivaroxaban, rivaroxaban and activated charcoal - Healthy | Phase 1 | Completed | Centre Hospitalier Universitaire de Saint Etienne | 12 | 2016-01-01 | 2016-05-25 |
| Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Budesonide/formoterol, Charcoal, Symbicort Turbuhaler - Asthma | Phase 1 | Completed | Orion Corporation, Orion Pharma | 20 | 2016-01-01 | 2017-03-08 |
| Clinical Study to Evaluate Z7200 Pharmacokinetics Profile Z7200 without oral activated charcoal, Symbicort Turbohaler without oral activated charcoal, Z7200 with oral activated charcoal - Asthma | Phase 1 | Completed | Zambon SpA | 91 | 2016-01-01 | 2022-02-23 |
| Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). SUN-101 via eFlow nebulizer, SUN-101 via eFlow nebulizer with activated charcoal, Seebri® Breezhaler® - COPD | Phase 1 | Completed | Sunovion Respiratory Development Inc. | 30 | 2015-10-01 | 2018-10-25 |
| A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers Z7200 without oral activated charcoal, Symbicort Turbohaler without oral activated charcoal, Z7200 with oral activated charcoal - Asthma | Phase 1 | Completed | Zambon SpA | 90 | 2014-09-01 | 2022-02-23 |
| Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus Salmeterol/fluticasone Easyhaler, Salmeterol/fluticasone Easyhaler with charcoal, Seretide Diskus - Asthma | Phase 1 | Completed | Orion Corporation, Orion Pharma | 129 | 2014-06-01 | 2015-09-29 |
| Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers. Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend), Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend), Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend) - Asthma | Phase 1 | Completed | GlaxoSmithKline | 60 | 2013-10-21 | 2018-06-19 |
| Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus Seretide Diskus and charcoal, Seretide Diskus, SF Easyhaler and charcoal - Asthma | Phase 1 | Completed | Orion Corporation, Orion Pharma | 48 | 2013-05-01 | 2014-01-03 |
| Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus Seretide Diskus and charcoal, Seretide Diskus, SF Easyhaler and charcoal - Asthma | Phase 1 | Completed | Orion Corporation, Orion Pharma | 50 | 2013-01-01 | 2014-01-03 |
Showing 20 of 28. Sign in to see all of them.
Asthma (10) · Anthrax (4) · Pulmonary Disease, Chronic Obstructive (4) · Poisoning (2) · Depressive Disorder, Major (1) · Diabetes Mellitus, Type 2 (1) · Hypersensitivity (1) · Sleep Initiation and Maintenance Disorders (1)
Orion Corporation, Orion Pharma (11) · Centre Hospitalier Universitaire de Saint Etienne (2) · Eli Lilly and Company (2) · GlaxoSmithKline (2) · Zambon SpA (2) · AstraZeneca (1) · Bristol-Myers Squibb (1) · DynPort Vaccine Company LLC, A GDIT Company (1) · Hoffmann-La Roche (1) · PharmAthene, Inc. (1) · Sanofi (1) · Sunovion Respiratory Development Inc. (1) · Unither Pharmaceuticals, France (1) · Viatris Innovation GmbH (1)
Finland (10) · United States (6) · United Kingdom (5) · France (4) · Australia (1) · Germany (1) · Turkey (Türkiye) (1)
Leena Mattila, MD, PhD (3) · Iissa Kivisto (1) · Irja Korpela, MSc (1) · Jeffrey Wald, MD (1) · Kimmo Ingman, MD, PhD (1)
PMID 21079762, PMID 27910037, PMID 30055824, PMID 31253162, PMID 38926266, PMID 41677208
2015 (2), 2019 (2), 2014 (1), 2017 (1)